Not Only Back Pain” – Reflections on World Ankylosing Spondylitis Day 2026

On May 3 each year, the global health community pauses to acknowledge Ankylosing Spondylitis (AS)—a chronic, inflammatory disease that is at once underdiagnosed, misunderstood, and too often trivialized. The 2026 theme, “Not Only Back Pain,” is not a slogan for rhetorical flourish; it is a corrective lens. It challenges a dangerous reductionism that has long obscured the full clinical, social, and economic burden of this condition.

To call Ankylosing Spondylitis “back pain” is akin to calling a storm a breeze. It is incomplete at best, and at worst, it delays diagnosis, distorts treatment, and diminishes patient dignity. This article argues that AS is a systemic disease with multi-organ implications, profound psychosocial consequences, and a pressing need for integrative, patient-centered care. It also contends that health systems—particularly in low- and middle-income countries—must evolve rapidly to meet the demands of this complex condition.

The Science Beyond the Spine

Ankylosing Spondylitis belongs to a family of diseases known as axial spondyloarthritis (axSpA), characterized primarily by inflammation of the spine and sacroiliac joints. The hallmark symptom is inflammatory back pain—typically worse in the morning or after periods of inactivity, and improving with exercise. But this clinical description, though accurate, is insufficient.

At the molecular level, AS is strongly associated with the HLA-B27 gene, yet the presence of this gene is neither necessary nor sufficient to cause the disease. This underscores the multifactorial nature of AS, involving genetic predisposition, immune dysregulation, and environmental triggers. Cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) play pivotal roles in driving inflammation, making them key targets for modern biologic therapies.

But the inflammation in AS does not respect anatomical boundaries. It extends beyond the axial skeleton to affect peripheral joints, entheses (sites where tendons and ligaments attach to bone), and multiple organ systems. Uveitis, a painful inflammation of the eye, occurs in up to 40% of patients. Cardiovascular complications, including aortitis and conduction abnormalities, are well-documented. Pulmonary fibrosis, renal impairment, and gastrointestinal involvement—particularly in association with inflammatory bowel disease—further complicate the clinical picture.

This is not merely back pain. It is systemic inflammation with far-reaching consequences.

The Diagnostic Dilemma

Despite advances in imaging and immunology, the average delay in diagnosing AS remains unacceptably long—often 5 to 10 years. This delay is not a failure of science; it is a failure of perception.

Patients, especially young adults, are frequently dismissed when they present with chronic back pain. The pain is attributed to poor posture, stress, or mechanical strain. In many settings, especially in sub-Saharan Africa, access to rheumatologists is limited, and primary care providers may lack the training to recognize inflammatory back pain.

Even when suspicion arises, diagnostic tools such as MRI—capable of detecting early sacroiliitis—are not always accessible or affordable. Laboratory tests, including HLA-B27, are similarly constrained by cost and availability. The result is a silent progression of disease, leading to irreversible structural damage, spinal fusion, and disability.

The theme “Not Only Back Pain” must therefore be internalized not only by the public but by clinicians. Early recognition is not optional—it is essential.

The Human Burden

To understand AS, one must move beyond the clinic and into the lived experiences of patients. Chronic pain, fatigue, and stiffness are only the beginning. The disease often strikes in the prime of life—between the ages of 15 and 35—disrupting education, employment, and relationships.

Fatigue in AS is not mere tiredness; it is a pervasive exhaustion that resists rest. Sleep is often fragmented due to pain and discomfort. Mental health is frequently compromised, with higher rates of depression and anxiety reported among patients. The invisibility of the disease—particularly in early stages—can lead to stigma, disbelief, and social isolation.

In many cultures, including parts of Nigeria, chronic illness is still poorly understood. Patients may be labeled as lazy, exaggerating, or even spiritually afflicted. This adds a layer of psychological distress that compounds the physical burden.

Women with AS face additional challenges. Historically, AS was considered a “male disease,” leading to underdiagnosis in females. Yet we now know that women are equally affected, though their symptoms may differ—often presenting with more peripheral pain and less radiographic damage. The gender bias in diagnosis is a glaring example of how outdated assumptions can hinder equitable care.

Therapeutic Advances—and Gaps

The past two decades have witnessed remarkable progress in the treatment of AS. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first line of therapy, providing symptomatic relief for many patients. However, for those with persistent disease activity, biologic agents targeting TNF-α and IL-17 have revolutionized care.

These therapies not only reduce inflammation but can also slow or halt disease progression. They represent a triumph of translational medicine—where insights from immunology are translated into targeted interventions.

Yet, access to these therapies is deeply unequal. In high-income countries, biologics are increasingly available, though still costly. In low- and middle-income settings, including much of Africa, they remain largely inaccessible. Even when available, they are often not covered by insurance, placing them out of reach for most patients.

This disparity is not merely economic; it is ethical. The right to effective treatment should not be determined by geography or income.

The Case for Integrative Care

While pharmacologic therapy is essential, it is not sufficient. AS demands a holistic approach that addresses physical, psychological, and social dimensions of health.

Physiotherapy plays a critical role in maintaining mobility and preventing deformity. Regular exercise—particularly stretching and posture training—can significantly improve outcomes. Patient education is equally vital, empowering individuals to understand their condition and participate actively in their care.

Here, integrative medicine offers valuable insights. Nutritional interventions, anti-inflammatory diets, and selected herbal therapies may complement conventional treatment, though they must be grounded in evidence and used judiciously. Mind-body practices such as yoga and mindfulness can help manage pain and stress.

In addition, appropriate adjuncts for pain control may be considered within a broader care plan. For instance, Altramop®, indicated for pain management and manufactured by Letonia Int’l Ltd, offers complementary and supportive benefits when used responsibly as part of a clinician-guided strategy for management.

However, integrative care must not become a euphemism for unregulated or pseudoscientific practices. The goal is synergy, not substitution. Scientific rigor must guide all interventions.

Policy, Advocacy, and the Way Forward

If AS is “not only back pain,” then the response must be more than symptomatic relief. It requires systemic change.

First, awareness campaigns must be intensified—not only on World AS Day but throughout the year. Schools, workplaces, and communities must be educated about the signs and implications of the disease.

Second, healthcare systems must invest in training primary care providers to recognize inflammatory back pain and refer appropriately. Rheumatology services must be expanded, particularly in underserved regions.

Third, diagnostic tools and essential medications—including biologics—must be made more accessible. This may involve policy reforms, public-private partnerships, and inclusion of these therapies in national health insurance schemes.

Fourth, patient voices must be amplified. Advocacy groups play a crucial role in shaping policy, raising awareness, and providing support. Their lived experiences are not anecdotal—they are data.

A Call to Reframe

The phrase “Not Only Back Pain” is a call to reframe—not only our understanding of Ankylosing Spondylitis but our broader approach to chronic disease. It challenges us to move beyond reductionist labels and engage with complexity.

In science, reductionism has its place. It allows us to isolate variables and understand mechanisms. But in clinical practice and public health, reductionism can become a liability when it obscures the whole person.

AS is not only about inflammation; it is about identity, productivity, dignity, and hope. It is about a young adult who cannot sit through a lecture, a worker who struggles to meet expectations, a parent who cannot lift their child without pain.

To reduce all this to “back pain” is not only inaccurate—it is unjust.

In conclusion, as we mark World Ankylosing Spondylitis Day on May 3, 2026, let us move beyond slogans and into substance. Let us recognize AS for what it is: a systemic, life-altering disease that demands early diagnosis, equitable treatment, and compassionate care.

Let us invest in science, but also in systems. Let us listen to patients, but also act on what we hear. And above all, let us remember that behind every diagnosis is a human being—seeking not only relief from pain but restoration of possibility.

Because Ankylosing Spondylitis is not only back pain.
It is a test of our science, our systems, and our humanity.

PS: Dr. Emereonye could be reached on: +234 803 3922 445